首页|期刊导航|北京中医药|生血宝合剂对胃癌小鼠环磷酰胺所致贫血状况改善作用观察

生血宝合剂对胃癌小鼠环磷酰胺所致贫血状况改善作用观察OA

Clinical efficacy of Shengxuebao Mixture in treatment of mice with gastric cancer anemia caused by cyclophosphamide

中文摘要英文摘要

目的 观察生血宝合剂对胃癌小鼠环磷酰胺所致贫血的改善效果.方法 将70只雄性BALB/c裸鼠按随机数字表法分为空白对照组、胃癌模型组、胃癌贫血模型组、促红细胞生成素(EPO)组及生血宝低、中、高剂量组,每组10只.除空白对照组外,其他各组均构建胃癌模型;除空白对照组和胃癌模型组外,其他各组经腹腔注射环磷酰胺80 mg/(kg·d),连续4 d,制备胃癌相关性贫血模型.空白对照组、胃癌模型组、胃癌贫血模型组给予0.2 mL/d纯水灌胃,连续14 d;生血宝低、中、高剂量组分别给予生血宝合剂2.92、5.85、11.7 mL/(kg·d)灌胃,连续14 d;EPO组给予0.2 mL/d纯水灌胃,同时腹部皮下注射人重组EPO 150 IU/(kg·d),连续14 d.对比各组小鼠一般状态、体质量、血常规.结果 胃癌贫血模型组及各给药组外周血血红蛋白(HGB)、红细胞(RBC)、白细胞(WBC)、血小板(PLT)计数均呈先下降后回升趋势.给药第7天,与胃癌贫血模型组比较,胃癌模型组、EPO组HGB水平升高(P<0.05);给药第14天,与胃癌贫血模型组比较,EPO组HGB水平升高(P<0.05).给药第7天,生血宝中剂量组、EPO组HGB水平高于本组给药第0天(P<0.05);给药第14天,各给药组HGB水平升高(P<0.05).给药第7天,各给药组RBC计数与胃癌贫血模型组比较,差异无统计学意义(P>0.05);给药第14天,与胃癌贫血模型组比较,生血宝中、高剂量组RBC计数高(P<0.05).给药第7天,与胃癌贫血模型组比较,生血宝中、高剂量组WBC计数高(P<0.05);给药第14天,与胃癌贫血模型组比较,生血宝低剂量组WBC计数高(P<0.05).给药第7天,与胃癌贫血模型组比较,生血宝低、中剂量组PLT计数高(P<0.05);给药第14天,与胃癌贫血模型组比较,各给药组PLT计数均高(P<0.05).与空白对照组比较,胃癌贫血模型组精神状态较差,活动量明显减少,蜷缩成团,皮色灰暗发紫,体质量不同程度减轻.造模3 d后,小鼠食欲减少,出现个别死亡.与胃癌贫血模型组比较,各给药组一般状况改善.给药第7、14天,各给药组体质量比较,差异无统计学意义(P>0.05).与胃癌贫血模型组比较,生血宝各剂量组肝脏指数、脾脏指数、肾脏指数比较,差异无统计学意义(P>0.05);与胃癌模型组比较,生血宝中剂量组肾脏指数低(P<0.05).结论 生血宝合剂可在一定程度上改善胃癌贫血小鼠一般状态,提高小鼠外周血HGB和RBC计数,对WBC和PLT也有一定改善作用.

Objective To investigate the therapeutic effects of Shengxuebao Mixture on cyclophosphamide-induced anemia in mice with gastric cancer.Methods Seventy male BALB/c nude mice were randomly divided into a blank control group,gastric cancer model group,gastric cancer anemia model group,erythropoietin(EPO)group,and low-,medium-,and high-dose Shengxuebao Mixture groups according to a random number table,with 10 mice in each group.Except for the blank control group,the gastric cancer model was established in all groups.Except for the blank control group and gastric cancer model group,mice in the remaining groups received intraperitoneal injections of cyclophosphamide at 80 mg/(kg·d)for 4 consecutive days to establish the gastric cancer-related anemia model.The blank control group,gastric cancer model group,and gastric cancer anemia model group received purified water(0.2 mL/d)by gavage for 14 consecutive days.The low-,medium-,and high-dose Shengxuebao Mixture groups received Shengxuebao Mixture at doses of 2.92,5.85,and 11.7 mL/(kg·d),respectively,by gavage for 14 consecutive days.The EPO group received purified water(0.2 mL/d)by gavage combined with subcutaneous abdominal injection of recombinant human erythropoietin(rhEPO)at 150 IU/(kg·d)for 14 consecutive days.General condition,body weight,and routine blood parameters of the mice were compared among groups.Results Peripheral blood hemoglobin(HGB),red blood cell(RBC),white blood cell(WBC),and platelet(PLT)counts in the gastric cancer anemia model group and all treatment groups showed a trend of initial decrease followed by gradual recovery.On treatment day 7,compared with the gastric cancer anemia model group,HGB levels in the gastric cancer model group and EPO group were significantly increased(P<0.05).On treatment day 14,compared with the gastric cancer anemia model group,HGB levels in the EPO group were significantly increased(P<0.05).On treatment day 7,HGB levels in the medium-dose Shengxuebao Mixture group and EPO group were significantly higher than those on treatment day 0 in the same groups(P<0.05).On treatment day 14,HGB levels in all treatment groups were significantly increased(P<0.05).On treatment day 7,compared with the gastric cancer anemia model group,no significant differences in RBC counts were observed among the treatment groups(P>0.05).On treatment day 14,RBC counts in the medium-and high-dose Shengxuebao Mixture groups were significantly higher than those in the gastric cancer anemia model group(P<0.05).On treatment day 7,WBC counts in the medium-and high-dose Shengxuebao Mixture groups were significantly higher than those in the gastric cancer anemia model group(P<0.05).On treatment day 14,WBC counts in the low-dose Shengxuebao Mixture group were significantly higher than those in the gastric cancer anemia model group(P<0.05).On treatment day 7,PLT counts in the low-and medium-dose Shengxuebao Mixture groups were significantly higher than those in the gastric cancer anemia model group(P<0.05).On treatment day 14,PLT counts in all treatment groups were significantly higher than those in the gastric cancer anemia model group(P<0.05).Compared with the blank control group,mice in the model groups showed poor mental status,markedly reduced activity,curled posture,grayish-purple skin color,and varying degrees of body weight loss.Three days after modeling,reduced appetite and sporadic deaths were observed.Compared with the model groups,the general condition of mice in all treatment groups improved.On treatment days 7 and 14,there were no statistically significant differences in body weight among the treatment groups(P>0.05).Compared with the gastric cancer anemia model group,there were no statistically significant differences in liver,spleen,or kidney indices among the Shengxuebao Mixture groups(P>0.05).Compared with the gastric cancer model group,the kidney index in the medium-dose Shengxuebao Mixture group was significantly lower(P<0.05).Conclusion Shengxuebao Mixture can improve the general condition of mice with gastric cancer-related anemia to a certain extent,increase peripheral blood HGB levels and RBC counts,and also exert beneficial effects on WBC and PLT counts.

许晶;张立明;祁加敏;卢海瑞;米虽才;韩欣璞;陈信义;侯丽

北京中医药大学东直门医院血液肿瘤科,北京 100700宁夏医科大学药学院,宁夏 750004宁夏医科大学药学院,宁夏 750004宁夏回族医药研究所,宁夏 750021厦门市中医院肿瘤科,厦门 361009北京中医药大学东直门医院血液肿瘤科,北京 100700北京中医药大学东直门医院血液肿瘤科,北京 100700北京中医药大学东直门医院血液肿瘤科,北京 100700

生血宝合剂胃癌贫血环磷酰胺疗效小鼠

Shengxuebao Mixturegastric canceranemiacyclophosphamidecurative effectmice

《北京中医药》 2026 (4)

461-466,6

北京中医药大学东直门医院领军人才项目(DZMG-LJRC0002)国家中医药管理局高水平中医药重点学科建设项目中医血液病学(zyyzdxk-2023268)中央高校基本科研业务费专项资金资助(2024-JYB-JBZD-012)

10.16025/j.1674-1307.2026.04.006

评论